dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Kiri

Sotsiaalministeerium · 30. juuni 2020
Viit
1.4-2/2083-1
Registreeritud
30. juuni 2020
Dokumendi liik
Sissetulev kiri
Adressaat
ECHAMP - Office
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2020
Vastutaja
Eda Lopato (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Ravimiosakond)

Failid

  • 📎E-kiri.pdf71 KB
  • 📎ECHAMP Annual Report 2019.pdf1120 KB

Sisu (failidest)

Saatja: ECHAMP - Office <[email protected]> Saadetud: 29.06.2020 18:05 Adressaat: Tanel Kiik <[email protected]> Koopia: SM Info <[email protected]> Teema: ECHAMP Annual Report 2019 Dear Mr Kiik, We are pleased to attach a copy of ECHAMPs report of activities in 2019. You may also .Although written in a pre-Covid-19 world, its core messages remain as valid now as ever before.The European industry for homeopathic and anthroposophic medicines has been serving patients now for over 200 years and has a strong foundation in EU legislation. The EU institutions have succeeded in creating a system that allows patients the option of accessing safe, high quality homeopathic and anthroposophic medicinal products of their choice. The industry leads the way globally with its expertise in the manufacture of these products and we can be proud of the European heritage and global standing of this sector.ECHAMP and our members work hard to protect the future of this industry; we are determined to communicate the lasting relevance and value of these medicines and are committed to strive for greater integration of these therapies into health care.We continue to seek stronger support at European and national level, to facilitate an open and objective discussion on the benefits and potential of these medicines and their place in a well-functioning, forward-thinking, people-centred health system that balances curative services with preventive care and self- care.Now is the time for politicians and policy makers to support our industry in standing up for the peoples choice for these medicines.We wish you a safe return to a more normal way of life.Yours sincerely David Reckeweg-Lecompte Amandine OsetPresident Public Affairs Manager ECHAMP [email protected] Rue Washington 38-40B-1050 BrusselsT +32 2 649 94 40to ECHAMP e- newsPlease consider the environment before printing this email Annual Report 2019 Support our industry CHOICE in standing up for patient Contents 1 Words from the President David Reckeweg-Lecompte Homeopathic and anthroposophic medicines – support our industry in standing up for patient choice 4 A well-regulated sector, an established European industry 8 Pharmacopoeia – Towards a common quality standard 9 Spotlight on an industry 10 The global debate 12 Inside ECHAMP Words from the President A changing political landscape A long-standing and strong foundation The industry for In 2019, the European electorate sent some clear in European law messages to their politicians and policy makers, The EU institutions have succeeded in creating a putting pressure on the EU institutions to redefine system that allows patients the option of accessing homeopathic and their role in the face of a surge of concern for the safe, high quality homeopathic and anthroposophic environment. The new Commission has confirmed medicinal products of their choice. its commitment to implementing the UN goals for This sector has a strong foundation in EU anthroposophic sustainable development and has given priority to legislation (see page 4), first established in 1992 to supporting the Member States in improving the ensure free trade within the European Union and quality and sustainability of their health systems. freedom of choice for patients while safeguarding medicines: This sets a welcome context for our industry, quality and safety. Today, the industry is highly which can make a valuable contribution towards regulated and the European system ensures the same meeting these goals. high standards for quality and safety for these as for Standing up all medicinal products. An established, patient-led, In 2017, a report by the Homeopathic Medicinal sustainable industry Products Working Group of the Heads of Medicines for patient The European industry for homeopathic and Agencies substantiated the legitimacy for EU anthroposophic medicines has been serving patients regulation in this field – all 24 responding EU now for over 200 years. The industry is, largely, Member States except two (Cyprus and Malta) choice defined by the demand from prescribers and confirm the presence of a market for homeopathic patients for a wide range of products, providing medicinal products and therefore the practice of millions of EU citizens with their choice in homeopathy in their countries. healthcare. These medicines can be individually prescribed by a doctor or practitioner or selected Europe leads the way in a global context for self-medication for everyday ailments. The European industry continues to lead the way Companies offer a broad spectrum of products globally with its expertise in the manufacture of for individual patients, and the homeopathic and anthroposophic medicinal “We seek stronger industry is characterised by huge products. support from variety, with thousands of different The 2019 World Health Organisation Global politicians and starting materials, potencies and Report on Traditional and Complementary Medicine policy makers to dosage forms required for the (see page 10) confirms the use of homeopathy in 100 facilitate an open proper practice of the therapies. countries around the world. In his foreword, WHO and objective Despite the broad spectrum Director General, Dr Tedros Adhanom Ghebreyesus, discussion on the of products, its medicines describes traditional and complementary medicine benefits and have a negligible as an “…important and often underestimated health potential of these environmental impact. resource … to help tackle the unique health medicines.” challenges of the 21st century.” In many countries, David Reckeweg-Lecompte, President, ECHAMP such as India, Mexico, Switzerland, Germany and Luxembourg, the government’s commitment to these therapies is clear and strong (see page 11). The European Commission itself recognises the importance of ensuring patient choice in this sector, echamp annual report 2019 1 saying that “The current regulatory framework EU citizens have the fundamental right to The millions of users for homeopathic products ... strikes a balance access balanced and neutral information to enable between ensuring their quality and safety ... while them to choose the health care most suited to of homeopathy and at the same time giving citizens access to these their needs. In the changing global context, the products.” European political and regulatory conversation anthroposophic Nevertheless, in countries such as France, risks losing sight of the long-established Spain, UK and Australia, attacks on this sector are contribution that homeopathy and anthroposophic medicine do so because resulting in government restrictions on patient medicine make to the health challenges of our access to these medicines. Such moves fly in the times and the social and economic benefits of they experience real face of patient preferences and are out of step with these therapies. The European industry and the the global trend (see page 10). wider sector are determined to communicate the improvements to their We should be proud of the European heritage lasting relevance and value of these medicines. and global standing of this sector and work to We are committed to strive for greater integration health. protect its future. of these therapies into health care. Standing up for patient choice Looking forward The millions of users of homeopathy and As ECHAMP moves into 2020 with a new anthroposophic medicine do so because they management team, the ECHAMP Board of experience real improvements to their health (see Management warmly thanks former President, page 9). They are convinced of the benefits, have Dr Gesine Klein and General Secretary, Christiaan confidence in the high safety profile of these Mol for their dedication and achievements during medicines and express a high level of satisfaction their terms of office. We continue to build on this with these treatments. hard work to secure and improve the situation for Homeopathic and anthroposophic medicinal homeopathic and anthroposophic medicinal products, currently used in primary and clinical products in the EU. care across Europe, have an important role to play All parties share responsibility for this work in the face of major health challenges in the – whether industry, regulator, health professional, EU. They offer valuable treatment options for policy maker or politician. At ECHAMP, we seek health challenges such as multimorbidity, stronger commitment at European and at national polypharmacy, antimicrobial resistance, chronic level, to facilitate an open and objective discussion and non-communicable diseases and an ageing on the benefits and potential of these medicines. population. A substantial body of scientific It is time for politicians and policy makers to research demonstrates the effectiveness of these recognise and acknowledge the patients’ forms of treatment; a growing body of published preference and to support our industry in standing observational studies confirms their real-world up for the people’s choice for these medicines. effectiveness. They can contribute to the David Reckeweg-Lecompte took over from Dr Gesine sustainability of health systems by significantly Klein as President of ECHAMP in June 2019. reducing treatment costs. In this context, it is important to ask why, in Europe, is pluralism in health care not being encouraged? 2 echamp annual report 2019 Photo: ECHAMP Board of Management, The Board of Management is committed to October 2019 securing and improving the situation for homeopathic and anthroposophic medicinal products in the EU. echamp annual report 2019 3 Regulatory environment An established European industry A quick history of regulation of our sector A well-regulated This long-standing European industry has a strong foundation in EU law and has been serving patients In 1992, the Council of the European now for over 200 years. Legislation for homeopathic Communities stated in the preamble to Directive 92/73/EEC that homeopathy was sector, an medicinal products was first established in 1992 (see inset) with the aim of ensuring free trade within prescribed and used in all Member States. the European Union and freedom of choice for It directed the Member States to implement certain changes in their national legislation established patients while safeguarding quality and safety. Today, manufacturers in Europe work to the same to harmonise the market of homeopathic high quality and safety standards for these as for all products. In 2001, Directive 92/73/EEC was replaced by Directive 2001/83/EC on the European industry medicinal products and there are more than 12,000 registered homeopathic medicinal products in the Community code relating to medicinal EU Member States and more than 3,000 homeo- products for human use. The intention was to: pathic medicinal products with a marketing · Create a legal framework that would allow authorisation. patients access to the medicinal products of The EU institutions have succeeded in creating their choice provided that all precautions a system that allows the millions of users of these were taken to ensure the quality and safety. products the option of accessing safe, high quality · Provide users of these medicinal products medicinal products of their choice. However, the with a clear indication of their homeopathic implementation of the current legislative framework character and sufficient guarantees of quality is still not fully complete in all Member States[1], and safety which has led to a lack of uniform availability of the products. · Harmonize the rules relating to the manufacture, control and inspection An increasingly complex regulatory environment · Permit the circulation throughout the ECHAMP works hard to ensure that the specific Community of medicinal products which characteristics of homeopathic and anthroposophic are safe and of good quality. medicinal products are taken into account in an It resulted in a special simplified appropriate way when it comes to new guidelines registration procedure for homeopathic for our sector, in particular from the European medicinal products without therapeutic Medicines Agency (EMA) or the Heads of Medicines indications in a pharmaceutical form and Agencies (HMA). dosage which do not present a risk for the Although in principal the legislator foresaw patient. reasonable approaches for these products (see inset), In addition, the standard rules apply to the actual experience is that the regulatory burden the authorisation of homeopathic medicinal for the sector is increasing from year to year products with indication. However, the regarding administrative workload and technical legislation allows Member States to introduce dossier requirements. or retain in their territory specific rules for the preclinical tests and clinical trials of these products. This means they have the option to recognise the specific characteristics of [1] Study on the Availability of Medicinal homeopathic medicinal products. Products for Human Use, Matrix Insight, 2012 4 echamp annual report 2019 2019 activities – quality and safety sector. We hope that it will continue to invest resources into the work on appropriate Over a period of time, ECHAMP has given input implementation of regulation for homeopathic to diverse draft Question and Answer documents and anthroposophic medicinal products and to seek on quality from the Homeopathic Medicinal further opportunities to enter into dialogue with Products Working Group of the Heads of Medicines the industry. Agencies (HMPWG) of the HMA. In 2019, we were reassured to see that some of our comments have been accepted by HMPWG, who have adopted final versions of the Question and Answers documents on the quality of homeopathic medicinal products. The direct dialogue with HMPWG in 2018 was very helpful to foster a shared understanding of the daily practice of the manufacturing of homeopathic and anthroposophic medicinal products and its presentation in the product dossiers. However, on the topic of safety assessment of homeopathic and anthroposophic medicinal products, the discrepancies regarding the calculation of first safe dilutions between industry and the agencies persist. This particularly affects those products which are on the market in potencies between mother tincture and D8. ECHAMP maintains the position that the evaluation criteria should be based on transparent assessments of The direct dialogue with HMPWG scientific literature data as applied for conventional medicinal products. in 2018 was very helpful to foster a Increasing workload and rising fees shared understanding of the daily In common with the whole pharmaceutical sector, our industry is suffering from the increasing practice of the manufacturing of workload and rising fees for the lifecycle management of our existing products. This burden homeopathic and anthroposophic is all the more severe for our sector, where a huge number of products are needed to keep these medicinal products. therapies available for patients. The workload and heavy cost have the effect of preventing companies from investing in the development of new products or modern administration forms. We continue to recognise and appreciate the work of HMPWG and the effort it invests in this echamp annual report 2019 5 Pharmacovigilance data and for identifying patterns that suggest new safety information. It does not lend itself well to It is highly important Identification of medicinal products the complexity of our industry where we need to The European Medicines Agency (EMA) is currently distinguish between multiple similar products, for ECHAMP that the in the process of implementing the standards for example, ‘Echinacea angustifolia’, ‘Echinacea developed by the International Organization for purpurea’, ‘…extract’ and others, to specify the standards for processing Standardization (ISO) for the identification of exact grade of dilution or to differentiate between medicinal products (IDMP). This is done in a plants, plant extracts or drug to solvent relation. The data on the medicinal phased programme based on the four domains of process quickly becomes too complicated for those, master data in pharmaceutical regulatory processes: such as our sector, with high numbers of variables products include – where substance, product, organisation and referential to research. The EudraVigilance web reporting (SPOR). It is highly important for ECHAMP that application (EVWEB) can be used as an alternative relevant – a harmonised the standards for processing data on the medicinal but is also too complicated when dealing with high products include – where relevant – a harmonised numbers of cases. nomenclature which is nomenclature which is suitable to homeopathic medicinal products. Special requirements in some Member suitable to homeopathic ECHAMP has an observer status in this States: Article 16(3) of EU Directive 2001/83/EC project and also participates in the EMA task force confirms that homeopathic medicinal products medicinal products. meetings. Due to the relocation of EMA from registered under the special simplified registration London to Amsterdam, task force activities in procedure (Article 14) (see page 4) are exempt from 2019 were limited. The final version of the EU pharmacovigilance requirements. According to this Implementation Guide for IDMP/SPOR, the draft legislation, there are no EU reporting obligations of which was extensively commented by ECHAMP, for suspected adverse reactions for these registered is expected in the first quarter of 2020. products. In some Member States, certain obligations continue to exist based on national rules. Pharmacovigilance requirements: inconsistent and irregular The EMA is also responsible for the coordination of the EU pharmacovigilance system. In 2018, it was already becoming apparent that changes in the pharmacovigilance obligations for manufacturers of homeopathic medicinal products in the EU were resulting in inconsistent and irregular requirements. In 2019, the situation remained unchanged. The following examples illustrate this. EMA databases: Of concern to ECHAMP members is the usability of the EudraVigilance Data Analysis System (EVDAS), the central tool for finding and receiving individual case safety reports from the competent authorities, for medicinal product 6 echamp annual report 2019 echamp annual report 2018 7 Pharmacopoeia: European health policy aims to strengthen A new pilot project cooperation between Member States in order to An important step forward was made in 2019. improve access to medicines. On the one hand, After long discussions on the substance towards a the pharmaceutical system is related to European monograph work concerning the standard of policy and on the other hand, it is related to an assay in each monograph, and following the national laws. To promote availability and access example of colleagues of the traditional Chinese common quality to medicinal products, a first step is to ensure medicine group, a pilot project has been set up. harmonised standards of quality and safety. The Homoeopathic Working Party, which The European Directorate for the Quality elaborates monographs on the substances used standard of Medicines (EDQM) enables the development, in homeopathic preparations, is working on supports the implementation, and monitors the three pilot monographs: Calendula, Planta tota, application of quality standards which allow safe Chamomilla, Planta tota, and Arnica, Planta tota. use of medicinal products. These are also seen The aim is to develop a semi-quantitative high- as a scientific reference in the rest of the world. performance thin layer chromatography (HPTLC) It is therefore crucial for homeopathic and as a test. HPTLC is an enhanced form of thin-layer anthroposophic medicinal products to set chromatography that achieves a higher resolution quality standards for inclusion in the European and thus allows more accurate qualitative and Pharmacopoeia. quantitative assessments. EDQM has been working hard for many Once agreement has been reached on that, years on the transcription to the European a robust identity and quality test will have been Pharmacopoeia of the homeopathic manufacturing developed and also a test which allows to measure methods and the substance monographs from the and monitor stability for important quality German Homeopathic Pharmacopoeia and the markers that can be measured in relation to French Pharmacopoeia referring to homeopathic reference substances added in the HPTLC. manufacturing methods and substance The homeopathic medicines industry is very monographs. The work has been fruitful and conscious that agreeing on a common quality common standards have been agreed. standard will further strengthen the strong legal basis homeopathic medicines have in the EU. It is crucial for homeopathic and anthroposophic medicinal products to set quality standards for inclusion in the European Pharmacopoeia. 8 echamp annual report 2019 Spotlight ECHAMP’s new report, Homeopathic and Anthroposophic Medicinal Products in the EU – Spotlight on an Industry presents a comprehensive review of on an industry the sector, confirming high levels of awareness of homeopathy and anthroposophic medicine in many countries in Europe, with growing use of and demand for these medicines and positive attitudes of citizens towards these therapies. Use of The publication provides a unique and Homeopathy GERMANY AUSTRIA up-to-date profile of the sector for homeopathic in the and anthroposophic medicinal products in the European EU, outlining the demand for these medicinal 56% of Germans have 62% used homeopathic of Austrians have used Union medicines homeopathic medicines products, presenting the characteristics of this 70% of users are satisfied or very satisfied with the effectiveness and lack of side effects industry and summarising the evidence base that As a long-time underpins their use in health care. It is the only attentive user such source for summarised EU data on this sector and observer of BELGIUM and includes the results of detailed research with homeopathic ECHAMP members over a period of time. medicines, I have In her foreword to the report, Michèle Rivasi direct personal 69% of Belgian households use homeopathic medicines MEP welcomes it as “an authoritative source of experience of the information.” She confirms her commitment to important role this sector, saying, “Legislation for homeopathic these therapies Sales per inhabitant in € adjusted for GDP per capita medicinal products has deep roots in their broad play within and purchasing power standard (ex-factory prices 2013) use in the Member States. As a long-time attentive complementary Data not available user and observer of homeopathic medicines, I and integrative 0-2 Sales per inhabitant have direct personal experience of the important medicine. 2- 4 Sales per inhabitant role these therapies play within complementary Michèle Rivasi, Member of the 4+ Sales per inhabitant and integrative medicine. I am committed to European Parliament ensuring that they take their rightful place within European health care.” ECHAMP’s report confirms positive FRANCE 16% ITALY of Italians use BULGARIA attitude and high demand for homeopathic SPAIN homeopathy at and anthroposophic medicines. least once a year 77% of French people have used homeopathy 33% of Spanish have used homeopathy 69% trust homeopathy 64% of family doctors and pharmacists in Bulgaria recommend homeopathy for simple conditions 82% of users are satisfied or very satisfied with the outcome UK echamp annual report 2019 9 15% of the British population have used homeopathy The global The debate around homeopathy and comple- Homeopathy Research Institute tenth mentary and integrative medicine continues in anniversary both a European and a global context. In June, David Reckeweg-Lecompte, President debate In 2019, a new report from the World Health of ECHAMP, was pleased to attend, along with Organisation confirms the growth and importance other members of the ECHAMP Board, the 10th of traditional medicine, including homeopathy. Anniversary celebrations and 4th International Major scientific and regulatory events, organised Research Conference of Homeopathy Research by Homeopathy Research Institute and World Institute. Held in London, this was HRI’s biggest Traditional and Integrative Medicine Forum respectively, cast a and most international conference to date. 352 complementary global spotlight on the sector. attendees from 38 countries enjoyed a fast-paced medicine is programme as 75 researchers and medics presented an important World Health Organisation — new report on the very latest research in the field of homeopathy and often traditional and complementary medicine from 27 countries. In line with the ‘cutting edge’ underestimated A new report from the World Health Organisation, theme of the conference, key topics included health resource. the Global Report on Traditional and Complementary clinical research, fundamental research, qualitative Medicine 2019, charts the growth of traditional and research, lab-based studies and veterinary research. WHO Director General, Dr Tedros Adhanom complementary medicine (T&CM) over the past The event will be remembered for the highest Ghebreyesus twenty years, confirming that homeopathy is the quality scientific programme and as the biggest third most popular specific complementary event in homeopathy research to date. medicine after acupuncture and herbal medicine, used in 100 countries around the world. In his foreword to the report, WHO Director General, Dr Tedros Adhanom Ghebreyesus, calls on policy-makers, health professionals and the public to capitalise on the potential contribution of traditional and complementary medicine to “help tackle the unique health challenges of the 21st century”, saying that is “…an important and often underestimated health resource… especially in the prevention and management of lifestyle-related chronic diseases, and in meeting the health needs of ageing populations.” He argues that at a time when “consumer expectations for care are rising, costs are soaring, and most budgets are either stagnant or being reduced”, traditional medicine should be an option “offered by a well-functioning, people-centered health system that balances curative services with preventive care.” HRI London 2019 – 10 Years of HRI 10 echamp annual report 2019 Advancing global collaboration on regulation The sector fights back In January, ECHAMP helped sponsor the second In many countries, the government’s commitment World Integrated Medicine Forum in Goa, India, to homeopathy and anthroposophic medicine is on the regulation of homoeopathic medicinal clear and strong – for example, the investment in products. The theme was ‘Advancing Global the sector is manifest in India; the Mexican Senate Collaboration’ and the event was organised by has adopted new legislation regulating home- the Central Council for Research in Homeopathy, opathic medicine within the context of its new with the support of the Indian Ministry of Ayurveda, national health service; in the Swiss healthcare Yoga and Naturopathy, Unani, Siddha and system, homeopathy is on an equal footing with Homoeopathy (AYUSH). It was opened in person conventional medicine and the German and by Shri Sripad Yesso Naik, Honourable Minister Luxembourg governments have both recently of State for the Ministry of AYUSH. Participants confirmed their commitment to upholding access included representatives from World Health to homeopathy. However, in other countries, it is Organisation (WHO) and medicines agencies, becoming apparent that attacks on the sector by pharmacopoeia experts, and industry opponents of homeopathy are resulting in initiatives representatives from India and around the world. by governments that restrict patient access to these Despite the growing demand for homeopathic medicines, for example the French government’s medicines globally, standards for the regulation decision to stop funding the reimbursement of of these medicines are highly disparate between homeopathic medicinal products, the Spanish different countries and this directly affects their government’s national plan against what they call availability. There is an opportunity for the EU, ‘pseudotherapies’ and the decision in June 2018 by with its expertise in the manufacture and regulation National Health Service (NHS) England to stop of homeopathic medicines, to endorse its funding homeopathic medicines. responsibility as global leader in this field and play In 2019, patients and prescribers were more David Reckeweg-Lecompte, President of ECHAMP, a role in ensuring safety and security for this vocal than ever before, standing up for their right meets Shri Sripad Yesso Naik, Honourable Minister growing demand. to use the medicines of their choice. More than of State for the Ministry of AYUSH. Christiaan Mol, then General Secretary of 1.3 million people in France have signed a petition ECHAMP, gave a strategic perspective on how to in favour of upholding the reimbursement of advance international collaboration in this field, homeopathic medicines; in response to intense and presenting different scenarios based on lessons global public pressure to put the record straight, learnt to date. Australia’s leading research institute, the National Health and Medical Research Council (NHMRC) publicly confirmed and clarified that ‘Contrary to some claims, the [2015 Information Paper on homeopathy] did not conclude that homeopathy was ineffective.’ In 2019, patients and prescribers were more vocal than ever before. echamp annual report 2019 11 Inside Membership Assembly In April, ECHAMP hosted a lively workshop for chief and senior executives of the EU industry ECHAMP for homeopathic and anthroposophic medicinal products in Dublin, as part of its annual Membership Assembly activities. Representatives from 26 companies across the EU and EFTA and representatives of some industry associations joined intensive strategic discussions aimed at helping frame the future of the sector. The Membership Assembly itself was chaired by Martin Murray of New Vistas Healthcare. In recognition of his many years of involvement, Martin was appointed as Honorary Member of ECHAMP. New President, new management In April, the Board of management of ECHAMP unanimously elected David Reckeweg-Lecompte to be its new President, taking over from Dr Gesine Klein, ECHAMP’s President since 2013. Christiaan Mol, General Secretary for the same period, also came to the end of his term. Both Gesine and Christiaan remain active in the association, ensuring a smooth transition to the new management and the continuity of certain projects. As ECHAMP moves into 2020, the new From left to right: management team members are settling into their Dr Gesine Klein, David Reckeweg- roles, with individual board members taking on Lecompte and Christiaan Mol different responsibilities. The Board of Management remains determined to build on the hard work of the previous team and to continue its work to improve the situation for homeopathic and anthroposophic medicinal products in the EU. ECHAMP Membership Assembly, Dublin 2019 12 echamp annual report 2019 ECHAMP membership 2019 41 Full Members from 16 different EU Member States plus Norway and one Extraordinary Member from Switzerland. Full Member of ECHAMP Associated Partner of ECHAMP Sweden Extraordinary Member of ECHAMP Finland Norway Estonia Latvia Lithuania Denmark Netherlands United Ireland Kingdom Poland Germany Belgium Czech Republic Slovakia France Austria Hungary Switzerland Slovenia Romania Croatia Italy Bulgaria Spain Portugal Greece Malta Cyprus ECHAMP, the European Coalition on Homeopathic & Anthroposophic Medicinal Products, is the European association of companies that work closely together to ensure that they can meet the demand from users and prescribers across the EU for these products. It advocates in favour of an appropriate regulatory environment for these products in the EU. ECHAMP E.E.I.G. Rue Washington 40 B-1050 Brussels T +32 2 649 94 40 E [email protected] www.echamp.eu Printed on Cyclus, 100% recycled with post consumer waste and no optical bleaching agents © ECHAMP 2020 16 echamp annual report 2019 Design: www.letterg.co.uk
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel